NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled
NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT07216443 2026-02-23Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeOrca Biosystems, Inc.Phase 2 Recruiting80 enrolled
NCT03229200 2025-10-30Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Pharmacyclics Switzerland GmbHPhase 4 Active not recruiting297 enrolled
NCT03320642 2025-10-21GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseIncyte CorporationPhase 1 Terminated84 enrolled
NCT03790332 2025-10-21Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Pharmacyclics LLC.Phase 1/2 Completed59 enrolled 1 FDA
NCT06462365 2025-04-15Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)Tr1X, Inc.Phase 1 Recruiting36 enrolled